Latest Headlines

Latest Headlines

Baxalta to Shire: We're young, we're just starting to grow, and we're rejecting your buyout offer

Baxalta CEO Ludwig Hantson Tuesday, Shire went public with a $30 billion bid for Baxalta that had already been rejected once. And the second time around, Baxalta had the same answer:...

Baxalta responds to a frustrated Shire: The answer is still 'no'

Baxalta execs didn't like the idea of a $30 billion all-share Shire buyout when they heard it the first time on July 10--and they didn't warm to it at all when Shire decided to go public with the offer Tuesday morning.

Philips on the hunt for more deals amid HealthTech refocus

Royal Philips has been on the dealmaking circuit since separating out its lighting business last year, scouting out partnerships and hospital contracts to beef up its new consumer healthcare unit. And the company is hungry for more M&A, working with Bank of America to scout out medical device acquisitions to bolster its offerings.

Deal-minded Shire offers $30B for new spinoff Baxalta in public bid

Shire announced on Tuesday that it put forth a bid of about $30 billion for Baxter spinoff Baxalta on July 10--just 9 days after Baxalta went solo--and now it's taking the offer to shareholders to spur the company to the bargaining table.

UPDATED: Shire goes public with a $30B bid to acquire Baxalta, expand rare-disease pipeline

After getting stiff-armed by the newly independent management at Baxter's biotech spinoff Baxalta, Shire is going public with its offer to acquire the company for $30.6 billion in shares. The deal marks Shire CEO Flemming Ornskov's play to make a landmark acquisition that can vault the company into the big leagues, after being left at the altar last year by AbbVie.

We warned you, Depomed: Horizon pushes down hostile path

Horizon Pharma is done playing nice in its quest to nab Depomed. Now that its target has dismissed its updated buyout bid, it's charging full-force into hostile pursuit.

UPDATED: Shire chief Ornskov bets $300M on another eye drug bolt-on buyout

Shire CEO Flemming Ornskov is spending $300 million of his cache of cash on a new ophthalmology buyout. Ornskov has pulled the trigger on a deal to snap up Foresight Biotherapeutics, adding a new bolt-on group with plans to take an eye drug into Phase III.

PRA bolsters eClinical suite with tuck-in acquisition

PRA plans to integrate the acquired assets into its nascent Predictivv platform and in doing so continue its attempts to use IT to stand out from the CRO crowd.

Ackman's 'wolf pack' drove Allergan into foreign hands, former CEO says

Former Allergan CEO David Pyott and activist investor Bill Ackman called each other plenty of things during last year's months-long Valeant-Allergan takeover battle. But Pyott had a new one during a Senate committee hearing on Thursday.

ResMed acquires China's Curative Medical to get bigger in sleep disorder devices

ResMed increased its focus on sleep disorder devices by acquiring China's Curative Medical for an undisclosed sum, in an attempt to gain a foothold in a fast-growing market.